Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.

Wael A. Harb,Nehal J. Lakhani,Ana Logsdon,Mary Steigelman,Heidi Smith-Green,Shari Kay Gaylor,Michael Woolliscroft,Wendi V. Rodrigueza,Mina Patel Sooch,Richard A. Messmann,Ayad Al-Katib

Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.

2014

Wael A. Harb
Nehal J. Lakhani
Ana Logsdon
Mary Steigelman
Heidi Smith-Green
Shari Kay Gaylor
Michael Woolliscroft
Wendi V. Rodrigueza
Mina Patel Sooch
Richard A. Messmann
Ayad Al-Katib

2586 Background: PNT2258 contains PNT100, a DNA interference (DNAi) oligonucleotide encapsulated in a lipid nanoparticle. PNT2258 targets the BCL2 gene and is undergoing evaluation in patients with...

Keywords:

dnaI
DNA
Pathology
Cancer research
Medicine
Refractory Non-Hodgkin Lymphoma
Pharmacokinetics
Oligonucleotide
Gene
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations